Torthaí cuardaigh - Yoshitaka Narita
- 1 - 20 toradh as 60 á dtaispeáint
- Téigh chuig an gcéad leathanach eile
-
1
Drug Review: Safety and Efficacy of Bevacizumab for Glioblastoma and Other Brain Tumors de réir Yoshitaka Narita
Foilsithe / Cruthaithe 2013Revisão -
2
Bevacizumab for glioblastoma de réir Yoshitaka Narita
Foilsithe / Cruthaithe 2015Revisão -
3
Trends and Outcomes in the Treatment of Gliomas Based on Data during 2001–2004 from the Brain Tumor Registry of Japan de réir Yoshitaka Narita, Soichiro Shibui
Foilsithe / Cruthaithe 2015Artigo -
4
Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma de réir Kaishi Satomi, Makoto Ohno, Yuko Matsushita, Masamichi Takahashi, Yasuji Miyakita, Yoshitaka Narita, Koichi Ichimura, Akihiko Yoshida
Foilsithe / Cruthaithe 2020Artigo -
5
In Vivo Study of the Efficacy and Safety of 5-Aminolevulinic Radiodynamic Therapy for Glioblastoma Fractionated Radiotherapy de réir Junko Takahashi, Shinsuke Nagasawa, Motomichi Doi, Masamichi Takahashi, Yoshitaka Narita, Junkoh Yamamoto, Mitsushi Ikemoto, Hitoshi Iwahashi
Foilsithe / Cruthaithe 2021Artigo -
6
Accelerator-based BNCT for patients with recurrent glioblastoma: a multicenter phase II study de réir Shinji Kawabata, Minoru Suzuki, Katsumi Hirose, Hiroki Tanaka, Takahiro Katō, Hiromi Goto, Yoshitaka Narita, Shin‐Ichi Miyatake
Foilsithe / Cruthaithe 2021Artigo -
7
Pivotal role for ROS activation of p38 MAPK in the control of differentiation and tumor-initiating capacity of glioma-initiating cells de réir Atsushi Sato, Masashi Okada, Keita Shibuya, Eriko Watanabe, Shizuka Seino, Yoshitaka Narita, Soichiro Shibui, Takamasa Kayama, Chifumi Kitanaka
Foilsithe / Cruthaithe 2013Artigo -
8
High Level Calcineurin Activity Predisposes Neuronal Cells to Apoptosis de réir Akio Asai, Jianhua Qiu, Yoshitaka Narita, Shunji Chi, Nobuhito Saito, Nobusada Shinoura, Hirofumi Hamada, Yoshiyuki Kuchino, Takaaki Kirino
Foilsithe / Cruthaithe 1999Artigo -
9
Safety and efficacy of tumour-treating fields (TTFields) therapy for newly diagnosed glioblastoma in Japanese patients using the Novo-TTF System: a prospective post-approval study de réir Ryo Nishikawa, Fumiyuki Yamasaki, Yoshiki Arakawa, Yoshihiro Muragaki, Yoshitaka Narita, Shota Tanaka, Shigeru Yamaguchi, Akitake Mukasa, Masayuki Kanamori
Foilsithe / Cruthaithe 2023Artigo -
10
IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy de réir Yoshiko Okita, Yoshitaka Narita, Yasuji Miyakita, Makoto Ohno, Yuko Matsushita, Shintaro Fukushima, Minako Sumi, Koichi Ichimura, Takamasa Kayama, Soichiro Shibui
Foilsithe / Cruthaithe 2012Artigo -
11
Resveratrol promotes proteasome-dependent degradation of Nanog via p53 activation and induces differentiation of glioma stem cells de réir Atsushi Satō, Masashi Okada, Keita Shibuya, Eriko Watanabe, Shizuka Seino, Kaori Suzuki, Yoshitaka Narita, Soichiro Shibui, Takamasa Kayama, Chifumi Kitanaka
Foilsithe / Cruthaithe 2013Artigo -
12
Erratum to: Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas de réir Hideyuki Arita, Yoshitaka Narita, Yuko Matsushita, Shintaro Fukushima, Akihiko Yoshida, Hirokazu Takami, Yasuji Miyakita, Makoto Ohno, Soichiro Shibui, Koichi Ichimura
Foilsithe / Cruthaithe 2017Errata/Corrigenda -
13
Childhood, adolescent and young adult cancer incidence in Japan in 2009–2011 de réir Kota Katanoda, Akiko Shibata, Tomohiro Matsuda, Megumi Hori, Kayo Nakata, Yoshitaka Narita, Chitose Ogawa, Wataru Munakata, Akira Kawai, Hiroshi Nishimoto
Foilsithe / Cruthaithe 2017Artigo -
14
Investigator-initiated phase I trial of an oligonucleotide therapeutic targeting long noncoding RNA TUG 1 for recurrent glioblastoma de réir Shoichi Deguchi, Fumiharu Ohka, Yoshiki Shiba, Junya Yamaguchi, Aya Sato, Keiko Shinjo, Yoshiki Arakawa, Yoshitaka Narita, Yutaka Kondo, Ryuta Saito
Foilsithe / Cruthaithe 2025Artigo -
15
Clinical characteristics and prognosis of Glioblastoma patients with infratentorial recurrence de réir Daisuke Kawauchi, Makoto Ohno, Mai Honda‐Kitahara, Yasuji Miyakita, Masamichi Takahashi, Shunsuke Yanagisawa, Yukie Tamura, Miyu Kikuchi, Koichi Ichimura, Yoshitaka Narita
Foilsithe / Cruthaithe 2023Revisão -
16
Revisiting <scp><i>TP</i></scp><i>53</i> Mutations and Immunohistochemistry—A Comparative Study in 157 Diffuse Gliomas de réir Hirokazu Takami, Akihiko Yoshida, Shintaro Fukushima, Hideyuki Arita, Yuko Matsushita, Taishi Nakamura, Makoto Ohno, Yasuji Miyakita, Soichiro Shibui, Yoshitaka Narita, Koichi Ichimura
Foilsithe / Cruthaithe 2014Artigo -
17
Targeting JNK for therapeutic depletion of stem-like glioblastoma cells de réir Kenichiro Matsuda, Atsushi Satō, Masashi Okada, Keita Shibuya, Shizuka Seino, Kaori Suzuki, Eriko Watanabe, Yoshitaka Narita, Soichiro Shibui, Takamasa Kayama, Chifumi Kitanaka
Foilsithe / Cruthaithe 2012Artigo -
18
Significance of <i>IDH</i> mutations varies with tumor histology, grade, and genetics in Japanese glioma patients de réir Akitake Mukasa, Shunsaku Takayanagi, Kuniaki Saito, Junji Shibahara, Yusuke Tabei, Kazuhide Furuya, Takafumi Ide, Yoshitaka Narita, Ryo Nishikawa, Keisuke Ueki, Nobuhito Saito
Foilsithe / Cruthaithe 2011Artigo -
19
Crosstalk Between the PI3K/mTOR and MEK/ERK Pathways Involved in the Maintenance of Self-Renewal and Tumorigenicity of Glioblastoma Stem-Like Cells de réir Jun Sunayama, Kenichiro Matsuda, Atsushi Satō, Ken Tachibana, Kaori Suzuki, Yoshitaka Narita, Soichiro Shibui, Kaori Sakurada, Takamasa Kayama, Arata Tomiyama, Chifumi Kitanaka
Foilsithe / Cruthaithe 2010Artigo -
20
Glioma-Initiating Cell Elimination by Metformin Activation of FOXO3 via AMPK de réir Atsushi Sato, Jun Sunayama, Masashi Okada, Eriko Watanabe, Shizuka Seino, Keita Shibuya, Kaori Suzuki, Yoshitaka Narita, Soichiro Shibui, Takamasa Kayama, Chifumi Kitanaka
Foilsithe / Cruthaithe 2012Artigo
Uirlisí cuardaigh:
Ábhair a bhaineann le hábhar
Medicine
Cancer research
Biology
Internal medicine
Gene
Glioma
Oncology
Genetics
Pathology
Chemotherapy
Biochemistry
Cancer
Glioblastoma
IDH1
Mutation
Radiation therapy
Cell biology
Adverse effect
Gastroenterology
Mutant
Physics
Radiology
Temozolomide
Clinical trial
Immunology
Stem cell
Surgery
Astrocytoma
Computer science
Confidence interval